Advertisement

Elexacaftor-Tezacaftor-Ivacaftor improve Gastro-Oesophageal reflux and Sinonasal symptoms in advanced cystic fibrosis

      Highlights

      • Upper airway and upper gastrointestinal disease are common in advanced CF.
      • CFTR modulators improve sinonasal and gastro-oesophageal reflux symptoms.
      • This is important in the context of lung transplantation.

      Abstract

      Upper gastrointestinal and upper airway disease are common in cystic fibrosis (CF) and may contribute to lower airway infection and inflammation. In a longitudinal cohort study of 32 patients (23 men; median age 32.5 years) with advanced CF lung disease (median FEV1 24.8% predicted) starting elexacaftor-tezacaftor-ivacaftor, the reflux symptom index score fell from a pre-treatment median (IQR) of 15 (11-23) to 5 (2.8-7.3) (p<0.001), the Hull airway reflux score fell from a median of 26.5 (16.3-39) to 7.5 (4-12) (p<0.001), and the sinonasal outcome score from a median of 36.5 (22-24) to 20 (10-32) (p<0.001) at 6 months on treatment. Mean FEV1% predicted rose by 9.2 points, the median respiratory domain score of the CF Questionnaire-Revised rose by 27.8 points and mean body mass index rose by 2.6 kg/m2. In addition to improving lung function and weight, CFTR modulators improve upper airway and gastro-oesophageal reflux symptoms in advanced CF.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Cystic Fibrosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Middleton PG
        • Mall MA
        • Drevinek P
        • Lands LC
        • McKone EF
        • Polineni D
        • et al.
        Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele.
        N Engl J Med. 2019; 381: 1809-1819https://doi.org/10.1056/NEJMoa1908639
        • Sergeev V
        • Chou FY
        • Lam GY
        • Hamilton CM
        • Wilcox PG
        • Quon BS.
        The extrapulmonary effects of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis.
        Ann Am Thorac Soc. 2020; 17: 147-154https://doi.org/10.1513/AnnalsATS.201909-671CME
        • Ramos KJ
        • Pilewski JM
        • Taylor-Cousar JL.
        Challenges in the use of highly effective modulator treatment for cystic fibrosis.
        J Cyst Fibros. 2021; 20: 381-387https://doi.org/10.1016/j.jcf.2021.01.007
        • Robinson NB
        • DiMango E.
        Prevalence of gastroesophageal reflux in cystic fibrosis and implications for lung disease.
        Ann Am Thorac Soc. 2014; 11: 964-968https://doi.org/10.1513/AnnalsATS.201401-044FR
        • Kimple AJ
        • Senior BA
        • Naureckas ET
        • Gudis DA
        • Meyer T
        • Hempstead SE
        • et al.
        Cystic fibrosis foundation otolaryngology care multidisciplinary consensus recommendations.
        Int Forum Allergy Rhinol. 2022; : 1-15https://doi.org/10.1002/alr.22974
        • DiMango E
        • Overdevest J
        • Keating C
        • Francis SF
        • Dansky D
        • Gudis D.
        Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis.
        J Cyst Fibros. 2021; 20: 460-463https://doi.org/10.1016/j.jcf2020.07.002
        • Beswick DM
        • Humphries SM
        • Balkissoon CD
        • Strand M
        • Vladar EK
        • Lynch DA
        • Taylor-Cousar JL.
        Impact of CFTR therapy on chronic rhinosinusitis and health status: deep learning CT analysis and patient reported outcomes.
        Annals ATS. 2022; 19: 12-19https://doi.org/10.1513/AnnalsATS.202101-057OC
        • Reen FJ
        • Woods DF
        • Mooij MJ
        • Chroinin MN
        • Mullane D
        • Zhou L
        • et al.
        Aspirated bile: a major host trigger modulating respiratory pathogen colonisation in cystic fibrosis patients.
        Eur J Clin Microbiol Infect Dis. 2014; 33: 1763-1771https://doi.org/10.1007/s10096-014-2133-8
      1. Al-momani H, Perry A, Stewart CJ, Jones R, Krishnan A, Robertson AG, et al. Microbiological profiles of sputum and gastric juice aspirates in cystic fibrosis patients. Scientific Reports 6:26985 doi: 10.1038/srep.26985.

        • Zeybel GL
        • Pearson JP
        • Krishnan A
        • Bourke SJ
        • Doe S
        • Anderson A
        • et al.
        Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation.
        J Cyst Fibros. 2017; 16: 124-131https://doi.org/10.1016/j.jcf.2016.07.004
        • McCormick J
        • Do-Yeon C
        • Lampkin B
        • Richman J
        • Hathorne H
        • Rowe SM
        • Woodworth BA.
        Ivacaftor improves rhinologic, psychologic, and sleep-related quality of life in G551D cystic fibrosis patients.
        Int Forum Allergy Rhinol. 2019; 9: 292-297https://doi.org/10.1002/alr.22251
        • Belafsky PC
        • Postma GN
        • Koufman JA.
        Validity and reliability of the reflux symptom index (RSI).
        J Voice. 2002; 16: 274-277https://doi.org/10.1016/s0892-1997(02)00097-8
        • Morice AH
        • Faruqi S
        • Wright CE
        • Thompson R
        • Bland JM.
        Cough hypersensitivity syndrome: a distinct clinical entity.
        Lung. 2011; 189: 73-79https://doi.org/10.1007/s00408-010-9272-1
        • Hopkins C
        • Gillett S
        • Slack R
        • Lund VJ
        • Browne JP.
        Psychometric validity of the 22-item sinonasal outcome test.
        Clin Otolaryngol. 2009; 34: 447-454https://doi.org/10.1111/j.1749-4486.2009.01995.x
        • Rowbotham NJ
        • Smith S
        • Leighton PA
        • Rayner OC
        • Gathercole K
        • Elliott ZC
        • et al.
        The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers.
        Thorax. 2018; 73: 388-390https://doi.org/10.1136/thoraxjnl-2017-210473
        • Burgel PR
        • Durieu I
        • Chiron R
        • Ramel S
        • Danner-Boucher I
        • Prevotat A
        • et al.
        Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease.
        Am J Respir Crit Care Med. 2021; 204: 64-73https://doi.org/10.1164/rccm.202011-41530C
        • Robertson AGN
        • Krishnan A
        • Ward C
        • Pearson JP
        • Small T
        • Corris PA
        • et al.
        Anti-reflux surgery in lung transplant recipients: outcomes and effects on quality of life.
        Eur Respir J. 2012; 39: 691-697https://doi.org/10.1183/09031936.00061811
        • Lauryn A
        • Benninger DO
        • Trillo C
        • Lascano J.
        CFTR modulator use in post lung transplant recipients.
        J Heart Lung Transplant. 2021; 40: 1498-1501https://doi.org/10.1016/j.healun.2021.08.009
        • Rowe SM
        • Heltshe SL
        • Gonska T
        • Donaldson SH
        • Borowitz D
        • Gelfond D
        • et al.
        Clinical mechanism of cystic fibrosis transmembrane conductance regulator potentiator Ivacaftor in G551D-mediated cystic fibrosis.
        Am J Respir Crit Care Med. 2014; 190: 175-184https://doi.org/10.1164/rccm.201404-07030C
        • Matsumoto Y
        • Shiozaki A
        • Kosuga T
        • Kudou M
        • Shimizu H
        • Arita T
        • et al.
        Expression and role of CFTR in human esophageal squamous cell carcinoma.
        Ann Surgical Oncology. 2021; 28: 6424-6436https://doi.org/10.1245/s10434-021-09752-y